Fig. 1.

Low serum levels of DC-SIGNR in lung cancer patients. The scatter plot displays DC-SIGNR levels in serum samples from 173 lung cancer patients and 134 healthy controls were tested by enzyme-linked immunosorbent assay (ELISA). Each point represents the serum DC-SIGNR level of one sample. The horizontal lines indicate the median levels. Serum DC-SIGNR was significantly lower in lung cancer patients compared with healthy controls (P = 0.0003) (a). Receiver operating characteristic (ROC) curve was used for serum DC-SIGNR in lung cancer prediction. A cut-off value of 3.8998 ng/L for DC-SIGNR to predict the presence of lung cancer with 78.03 % sensitivity and 49.25 % specificity (Area under curve (AUC) = 0.6212, P = 0.0003) (b)